ERASBullishERAS-0015 Phase 1 update and Phase 3 plannews
Medium materiality6/10
Erasca falls 5% as early RAS cancer data leave key questions unanswered
Nov 20, 2026, 9:43 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The Phase 1 response rates and the stated plan for a Phase 3 trial imply potential future commercial opportunity if durability and confirmatory outcomes hold; however, the absence of DOR/PFS/OS data leaves the revenue impact uncertain until registrational efficacy is demonstrated.
AI summary
What happened, with direct paths to the underlying reporting
Erasca reported updated Phase 1 ERAS-0015 data showing a 44% confirmed ORR (11/25) in 2L+ KRAS G12X pancreatic cancer and stronger responses (69%) in a G12D/V subgroup, and said it plans to begin a Phase 3 pancreatic trial in H1 2027.
At a once-daily dose of 32 milligrams, ERAS-0015 produced a 44% confirmed objective response rate in 25 patients with previously treated pancreatic ductal adenocarcinoma harboring KRAS G12X mutations.
The 44% ORR corresponds to 11 patients with confirmed tumor responses.
In a 13-patient subgroup with G12D or G12V mutations the confirmed response rate was 69% (63% in eight G12D patients and 80% in five G12V patients).
The company said it plans to begin a Phase 3 pancreatic cancer trial in the first half of 2027.
The announcement did not provide median duration of response, progression-free survival or overall survival.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event